The Pharmaceuticals Benefits Advisory Committee (PBAC) has recommended the listing of quadrivalent influenza vaccine (QIV, Vaxigrip TetraTM) on the National Immunisation Program (NIP) for the prevention of seasonal influenza in children aged 6 months to <5 years as well as for individuals who are currently eligible for seasonal influenza vaccination through the NIP in 2020.
About MVEC
The Melbourne Vaccine Education Centre (MVEC) is an educational website, developed with the aim of providing up-to-date immunisation information for both healthcare professionals and members of the public. We are based at Murdoch Children’s Research Institute (MCRI), a research organisation, and are affiliated with SAEFVIC (Surveillance of Adverse Events Following Vaccination in the Community), the Victorian Vaccine Safety Service.